Skinbiotherapeutics probe: ex-CEO accused of misrepresentation as company removes £770k of royalties and shares plunge nearly 70%

Key Highlights
Introduction
The company and the technology: what Skinbiotherapeutics does and why it mattered to investors
Timeline of the unfolding events
What the board disclosed and what it did not
The accounting issue: accrued royalty income and revenue recognition
The auditors’ role and the sequence that should follow
Market reaction: share price, expectations and the cash position
Governance failings and the responsibilities of the board
Regulatory and legal pathways: what may follow
Comparisons with past UK and global cases: lessons and parallels
Restoring trust: steps Skinbiotherapeutics can and should take
What removal of the accrued royalty income means for FY25 and FY26
Impact on customers, partners and employees
Financing and strategic options ahead
Broader implications for small-cap biotech governance on AIM
What stakeholders should watch next
Practical advice for investors and analysts
What this episode says about executive accountability
Concluding observations
FAQ

Key Highlights

Skinbiotherapeutics has opened an urgent investigation after its former CEO was accused of materially misrepresenting accrued royalty income; the board expects to remove £770,000 from FY25 accounts.
The announcement triggered a collapse in the company’s share price — falling from 19.52p to 5.95p in five days — and prompted the executive chairman to assume interim leadership while the company searches for a new CEO.
Directors say contracts and core technology remain sound, and the group retains a cash balance of £2.92m, but they now expect FY26 results to be significantly below market expectations.

Introduction

A small Newcastle-based biotech group that built investor confidence around skin microbiome technology has been rocked by allegations against its former chief executive. Skinbiotherapeutics Plc said an internal inquiry found grounds to believe its ex-CEO misrepresented material information to the board, auditors and advisors. That finding has prompted the company to seek the reversal of £770,000 of accrued royalty income from its audited accounts for the year ended 30 June 2025 and to launch a broader review of financial reporting and operations.

The news landed with force. The AIM-listed company’s shares plunged almost 70% in less than a week, wiping out investor gains that had accumulated over years of product and revenue development. Directors insist the business fundamentals — its SkinBiotix platform, partner contracts and near-term cash — remain intact. They also accept the incident is serious enough to require an independent, forensic-style probe and changes in leadership.

What began as a local management issue has turned into a case study in the fragile confidence that small-cap life-sciences companies face when governance, accounting and leadership intersect. This article explains what the board has disclosed, unpacks the accounting and governance issues at stake, places the episode in the context of similar corporate failures, and outlines the steps the company and its stakeholders will need to take to rebuild credibility.

The company and the technology: what Skinbiotherapeutics does and why it mattered to investors

Skinbiotherapeutics is headquartered at The Core on the Helix in Newcastle and markets products rooted in microbiome science with applications in wound care and skin health. Its SkinBiotix technology aims to influence the skin microbiome to promote healing and reduce infection risk, a proposition that attracted both clinical interest and commercial partners.

Since 2019 the company was led by Stuart Ashman, an experienced life sciences executive credited by the board with guiding a phase of commercial development. Under his stewardship Skinbiotherapeutics moved from early-stage R&D toward revenue-generating partnerships and product rollouts. For a small-cap biotech on AIM, demonstrating revenue growth and building a pipeline of licensing and royalty income are crucial signals to investors that the business has migrated from pure R&D risk toward commercial traction.

That trajectory made the company visible to retail and institutional investors who follow biotechnology and medtech opportunities on the junior market. Market analysts had expected Skinbiotherapeutics to report FY26 revenue of approximately £6.2m and an adjusted EBITDA around £700,000 — forecasts that underpinned investor valuation ahead of the investigation.

Timeline of the unfolding events

The sequence of public disclosures gives a clear—if incomplete—picture of how the incident escalated.

Prior to 12 February 2026: The business operated under normal public reporting cadence. The audited accounts for the year ended 30 June 2025 had been published, and the FY25 accounts included £770,000 of accrued royalty income.
12–13 February 2026: Concerns emerged within the board about the conduct of CEO Stuart Ashman. The board suspended him while it sought advice and conducted preliminary inquiries.
Late Friday 13 February 2026: Skinbiotherapeutics notified the market that it was urgently conducting an internal investigation and that newly available information cast doubt on the validity of accrued royalty income shown in the FY25 audited accounts.
Sunday 15 February 2026: The former CEO was formally informed of the allegations. He subsequently resigned.
16 February 2026: The company released an update to shareholders confirming that, based on initial findings, it has reason to believe the former CEO misrepresented material information to the board, senior management, auditors and advisers. The board expects to remove the £770,000 accrued royalty income from FY25 accounts, subject to auditor confirmation. Martin Hunt, the non-executive chairman, took on the role of executive chairman temporarily.

The speed of investor reaction — a near-70% share-price collapse in five days — underlines how rapidly confidence can erode when governance and accounting irregularities emerge.

What the board disclosed and what it did not

Skinbiotherapeutics’ market note is concise and cautious. The board stated it was “urgently conducting an investigation” and that it “has reason to believe” the former CEO misrepresented material information. Directors signalled they were taking two immediate actions:

Inform auditors and advisers and seek confirmation regarding the removal of the £770,000 of accrued royalty income from FY25 accounts.
Institute a broader review across the group’s businesses regarding financial reporting and operations.

The board also sought to reassure stakeholders that contracts with key partners remain sound, that management quality and product potential remain intact, and that the company had a robust cash balance of £2.92m as at 13 February 2026. The company said it is searching for both an interim CEO and a permanent successor.

What the update did not include were details about the nature of the alleged misrepresentation, the partners or contracts connected to the accrued royalty income, precise accounting entries affected beyond the accrual reversal, or whether the company’s nominated adviser, auditors and other external advisers had flagged the issue earlier. Those omissions are typical at the start of a probe but they leave the market with considerable uncertainty.

The accounting issue: accrued royalty income and revenue recognition

Accrued royalty income is an accounting entry reflecting revenue the company believes it has earned but not yet received in cash. It typically arises when contractual terms entitle the company to royalties based on partner sales or milestones, and management judges that revenue recognition criteria are met.

Credit to the accrual is only appropriate if the underlying event that gives rise to the royalty has occurred, the amount can be reliably measured, and collection is probable. Where any of these conditions is uncertain, recognised accruals may overstate revenue and profit. Auditors evaluate the evidence supporting such judgments and issue an opinion on whether the financial statements present a true and fair view.

In Skinbiotherapeutics’ case, the board’s initial finding is that information received late on 13 February casts “significant doubt” on the validity of the £770,000 accrued royalty income recorded in the FY25 audited accounts. The board expects those sums to be removed from the FY25 accounts, subject to confirmation by the auditors. Removing the accrual will reduce reported revenue and may change reported profit metrics for FY25; it also creates a knock-on effect for FY26 expectations, since analysts and investors had rolled that accrual into growth forecasts.

Why does this matter? For small public companies, the difference between modest reported revenue and nil revenue can materially affect investor perception, access to capital, and executive incentives. Accruals are inherently judgmental; they are an area where management estimation has to be carefully corroborated with contract documentation, partner confirmations and third-party data. When such corroboration fails — whether because of negligence, poor controls, or deliberate misrepresentation — the result is a loss of confidence in the entire financial reporting framework.

The auditors’ role and the sequence that should follow

Auditors are independent professionals appointed to provide assurance over a company’s financial statements. They test management’s assertions and assess whether accounting judgments have adequate supporting evidence.

When a board reports that it has informed auditors of initial findings, several actions typically follow:

The auditors will assess whether the newly discovered information amounts to a subsequent event that affects the audited financial statements.
If so, auditors will work with management to adjust and restate the accounts where necessary, or qualify their audit opinion if sufficient appropriate evidence cannot be obtained.
The auditors may expand substantive testing in the affected areas, and they may ask for third-party confirmations from customers or partners to validate royalty entitlements.
Depending on the severity, auditors may involve forensic accountants or request access to communications and contracts to verify the substance of the alleged misrepresentation.

If auditors conclude that the audited accounts were materially misstated, the company may be required to publish corrected accounts and the auditors may need to modify their auditor’s report. That process can be protracted, especially where legal questions — for example, about misrepresentation or fraud — arise.

Market reaction: share price, expectations and the cash position

Investor reaction was immediate and severe. Skinbiotherapeutics’ share price fell from 19.52p on Thursday 12 February to 5.95p by mid-morning on Monday 16 February — a decline of about 69% in five days. That magnitude of decline reflects more than the reversal of £770,000 in accrued royalties; it represents a widespread reassessment of management credibility, governance quality and the risk that further accounting issues will surface.

Directors sought to counter the panic with two financial facts: a healthy cash balance of £2.92m as of 13 February 2026, and a statement that underlying contracts remain sound. Cash at the bank provides near-term runway and reduces the immediate need for dilutive capital raising. However, for a company expecting revenue of £6.2m for FY26, the removal of nearly £0.77m from FY25 accounts and the board’s acknowledgement that FY26 results will be “significantly below current market expectations” both lower the valuation envelope and increase pressure on liquidity planning.

Smaller quoted companies often survive on a combination of operational cash generation and access to capital markets. A collapse in market value can make any future fundraise more dilutive and harder to execute. Moreover, lenders and partners may include covenant language or contract terms that respond negatively to adverse financial restatements. The board will need to manage communications carefully to avoid a liquidity squeeze.

Governance failings and the responsibilities of the board

The board’s statement that it has reason to believe the former CEO misrepresented information underscores that the alleged problem is not merely an accounting error but a potential governance breakdown. Boards have several responsibilities that touch on this episode:

Oversight of management and verification of material representations.
Proper functioning of internal controls over financial reporting and ensuring adequate segregation of duties.
Appointment and monitoring of external auditors and the audit committee’s role in challenging management estimates.
Ensuring the nominated adviser (Nomad) on AIM satisfies its responsibilities to the market, including due diligence on the company’s disclosures.

Non-executive directors are particularly important in small-cap companies because they are expected to provide independent challenge. If material information was misrepresented to the board and to auditors, it raises questions about how board oversight was exercised and the robustness of both internal controls and external reporting processes.

The temporary move of Martin Hunt from non-executive chairman to executive chairman suggests the board recognises the need for stronger day-to-day oversight while it navigates the investigation and searches for a new CEO. That is a common interim step in situations where the executive leadership team is in flux.

Regulatory and legal pathways: what may follow

When a company uncovers or suspects material misrepresentation by a senior executive, several regulatory and legal avenues may open:

Restatement of accounts and revised audit opinion: If auditors and management agree that the FY25 accounts contain material misstatements, corrected accounts will be published and investors will be notified through the market’s regulatory channels.
Investigation by regulators: In the UK, the Financial Conduct Authority (FCA) can investigate breaches of market rules or disclosure obligations. For AIM-quoted companies, the London Stock Exchange and the company’s Nomad have specific responsibilities for ensuring that communications to the market are accurate and timely. If the matter suggests fraud, the Serious Fraud Office or criminal authorities may become involved.
Civil litigation: Investors or counterparties who suffered loss could pursue civil claims against the company and, depending on the facts, against individuals alleged to have misrepresented information.
Employment and contractual disputes: The company may pursue internal disciplinary or legal action against former executives if misrepresentation breaches employment contracts or fiduciary duties.

At the outset, the board must balance the need for rapid disclosure with legal obligations and the risk that premature public statements could prejudice subsequent proceedings. That tension explains the measured nature of the company’s early statements.

Comparisons with past UK and global cases: lessons and parallels

Several high-profile corporate governance failures offer instructive parallels. While scale, sector and outcomes vary, recurring themes emerge: weak oversight, reliance on optimistic management judgments, and the erosion of investor trust.

Quindell (UK): Once a high-flying AIM-listed services group, Quindell faced allegations of accounting irregularities and aggressive revenue recognition. The company’s valuation collapsed, and regulatory investigations followed. Quindell’s experience shows how optimism in accounting for future revenue or contracts can be challenged and lead to severe reputational and financial consequences.
Conviviality (UK): The retail and wholesale group faced a sudden funding hole and disclosure missteps that precipitated insolvency. Conviviality’s collapse highlighted how quickly market confidence can evaporate when management fails to accurately disclose financial stress and risks.
NMC Health (UAE/LSE): NMC demonstrated the global consequences of governance failure when it emerged that the company had concealed debt and misstated its financial position. The case emphasises the need for thorough independent verification of financial statements and robust governance frameworks.
Wirecard (Germany): Although much larger and more complex, Wirecard is a cautionary tale about the depths of possible financial misrepresentation, the limits of audits that rely excessively on management-provided information, and the reputational havoc that follows.

These cases show that early, transparent, and thorough investigations — ideally performed by independent advisers and forensic accountants — are essential to contain damage and restore credibility. They also show that persistent opacity or delayed corrective action compounds investor losses and invites regulatory scrutiny.

Restoring trust: steps Skinbiotherapeutics can and should take

Rebuilding confidence will require decisive, transparent, and verifiable action across several dimensions.

Commission an independent forensic review
- The board should appoint an independent firm with forensic accounting experience to examine the specific allegations, the accounting entries in question, and whether similar issues exist elsewhere in the group. The reviewers should be empowered to access documents, communications and partner confirmations, and to report key factual findings to the board and, where appropriate, to regulators.
Work proactively with auditors and regulators
- The company should collaborate with its external auditors to assess whether accounts require restatement and to confirm audit trailing evidence for the FY25 figures. If regulatory disclosure obligations are triggered, the board should coordinate filings promptly and fully.
Strengthen board oversight and internal controls
- An immediate review of the audit committee’s workflow, internal control environment and management approvals is necessary. Consider appointing additional independent non-executive directors with relevant finance or sector experience to strengthen oversight.
Transparent, factual communication
- Provide regular, factual updates to the market as investigations progress, avoiding speculation while ensuring investors have the information necessary to assess ongoing risk. Where possible, publish timelines for key milestones: forensic review completion, auditor conclusions, and the search process for a new CEO.
Review incentive structures
- The board should examine whether executive incentives encouraged overly optimistic reporting or aggressive accounting, and adjust compensation and governance policies accordingly.
Preserve business continuity
- Communicate clearly with customers, partners and suppliers that contracts remain in force and that operations are continuing. Reassure clinical and regulatory partners about programme continuity. Prompt partner confirmations of royalty entitlements will be a valuable source of evidence for auditors.
Prepare for possible legal and regulatory outcomes
- Engage legal advisers to evaluate the potential for claims, to preserve evidence, and to ensure that the company’s actions are consistent with any ongoing or potential regulatory investigations.

Executing these steps quickly, comprehensively and transparently is the surest way to limit further damage.

What removal of the accrued royalty income means for FY25 and FY26

Removing £770,000 in accrued royalty income from FY25 accounts will reduce reported revenue and potentially affect reported EBITDA for the prior year. The FY25 audited accounts, as published, will need to be corrected if auditors concur with the board’s assessment. A restatement has implications beyond a single line item:

Earnings history: Analysts and investors often base forecasts on reported historical revenue. Restating FY25 lowers the baseline and will alter comparatives used in FY26 performance measurement.
Covenant and contractual effects: Some contracts and loan agreements contain clauses that trigger on material adverse changes in reported results. The company needs to review any covenants impacted by the restatement.
Market expectations: The board already warned that FY26 results will be “significantly below current market expectations.” The removal of the accrual is only part of that re-forecast; the board’s broader investigation could reveal additional adjustments or operational impacts.
Executive accountability: Restatements typically raise questions about internal review and the role of executive management and the audit committee, which may lead to executive departures, resignations, or formal disciplinary action.

Overall, the removal of accrued royalty income is material for a small-cap company. It reduces the reported revenue base and amplifies the need for clear evidence that the underlying business remains viable.

Impact on customers, partners and employees

Skinbiotherapeutics’ chief commercial asset is its SkinBiotix technology and partnerships that generate royalties or other revenue streams. The board said it concluded, after initial findings, that contracts with key partners and customers remain sound. That message is crucial; partner confidence underpins royalty income and future collaboration.

Nevertheless, major partners will want explicit confirmations and documentation. They may require additional audits, performance verification, or renegotiation of payment terms if uncertainty persists. Delays in partner payments could exacerbate cash-flow strain.

Employees and management teams face significant stress during governance crises. Leadership uncertainty and the public nature of the allegations can impact morale and retention. The company must manage staff communications carefully, ensure continuity of clinical programmes and protect IP and regulatory filings that underpin long-term value.

Financing and strategic options ahead

With a cash balance of £2.92m, Skinbiotherapeutics retains a degree of short-term stability. But for a company aiming to scale and deliver on commercial milestones, the options for preserving financial flexibility include:

Operational cost management: Tighten discretionary spending and extend runway where possible while preserving R&D and essential commercial activities.
Partner financing or milestone acceleration: Negotiate with partners for near-term advance payments against royalties or accelerate milestone-based payments where contractually feasible.
Equity fundraise: A capital raise will be more expensive in a depressed share-price environment. The board will need to weigh timing, quantum and dilution against urgency.
Debt facilities: Short-term loans or overdraft facilities may be considered, though lenders will demand covenants and security that could be onerous.
Asset or IP licensing: Consider monetising non-core assets or licensing technology rights to generate revenue without equity dilution.

Each route involves trade-offs and must be considered alongside reputational recovery efforts, which will determine investor willingness to participate.

Broader implications for small-cap biotech governance on AIM

The Skinbiotherapeutics episode highlights structural risks that affect many AIM-listed life-sciences companies:

Heavy reliance on management judgement: Small biotech firms often rely on optimistic projections and judgement-heavy accounting items (accruals, milestone recognition). That increases the importance of independent verification and rigorous audit committee oversight.
Board capacity: Growing companies require boards to scale their oversight capacity. Non-executive directors must be equipped to challenge technical, commercial and financial claims.
Disclosure cadence: Less frequent external scrutiny compared with larger companies means investors need timely, high-quality disclosures to assess progress and risk.
Concentration risk: Smaller companies can be highly dependent on a few key contracts or executives. Missteps by one person can have disproportionately large impacts on company valuation.

Investors and regulators have increasingly recognised these vulnerabilities. Strengthening governance frameworks, enhancing the role of Nomads, and improving audit committee practices on AIM are areas that may receive renewed attention as a result of cases like this.

What stakeholders should watch next

The market now awaits several critical milestones that will determine the company’s path:

Auditor findings: Whether the auditors confirm the board’s intention to remove the £770,000 accrual and whether further adjustments are required. An auditor-modified opinion would be serious.
Forensic review conclusion: The scope and conclusions of any independent investigation into the alleged misrepresentation.
CEO appointment and governance changes: The appointment of an interim and then a permanent CEO, and potential changes to the board or audit committee membership.
Revised FY26 guidance: Clear, updated financial forecasts and operating metrics reflecting the removal of accruals and other findings.
Partner confirmations: Public or private confirmations from major partners and customers about the status of royalty arrangements.
Any regulatory or legal actions: Notifications of formal investigations by regulators or the initiation of civil or criminal proceedings.

Timely, specific updates on these items will materially influence investor sentiment and the company’s ability to stabilise.

Practical advice for investors and analysts

For market participants assessing Skinbiotherapeutics and similar small-cap biotech equities, a pragmatic approach is warranted:

Demand documentation: Where possible, seek granular disclosure on the contracts and calculations underpinning accrued revenue items. Third-party partner confirmations are the strongest evidence.
Monitor audit output: The auditor’s report and any restated accounts will provide critical independent validation or repudiation of management claims.
Size positions to liquidity: Given volatility, ensure position sizes reflect the risk of further negative information and the potential for illiquidity in a small-cap stock.
Evaluate operational resilience: Distinguish between accounting irregularities and underlying commercial performance. A company with solid contracts, growing demand and intact IP is a different risk profile to one where those elements are compromised.
Consider governance indicators: Track board composition, the presence of an active and capable audit committee, and the engagement level of non-executive directors.

These best practices are general but are especially important for junior-market companies where the margin for error is small.

What this episode says about executive accountability

Accusations of misrepresenting material information strike at the heart of executive accountability. Corporate executives occupy positions of trust and have legal and fiduciary duties to the company and its shareholders. When they breach that trust — whether through recklessness or deliberate deception — the consequences can extend beyond the individual to affect employees, suppliers, patients (in the case of life sciences), and investors.

Boards must demonstrate that they will act impartially and thoroughly to preserve the integrity of financial reporting. Transparent remedial measures and, where warranted, appropriate disciplinary or legal outcomes are necessary to reinforce standards and deter future breaches.

Concluding observations

Skinbiotherapeutics faces a consequential period. The board has identified a potentially material misrepresentation and moved quickly to remove the implicated accrual, involve auditors and commence a wider review. The company retains cash and asserts its contracts and technology remain sound. Yet the market has rendered an immediate verdict: share prices collapsed and investor trust has been shaken.

The company’s ability to navigate the next stages — forensic review, auditor determinations, restatement if necessary, and leadership appointments — will determine whether Skinbiotherapeutics can recover credibility and continue its commercial trajectory. For investors, partners and employees, the coming weeks will either clarify the business’ underlying strength or reveal deeper problems. For the AIM market, the episode reinforces the long-standing need for robust governance, transparent disclosure and vigilant oversight in smaller quoted companies.

FAQ

Q: What exactly did Skinbiotherapeutics allege about its former CEO? A: The board said it has “reason to believe” the former CEO misrepresented material information to the board, senior management, the company’s auditors and advisers. The company did not publicly provide granular details of the alleged misrepresentation but stated the newly available information cast significant doubt on the validity of £770,000 of accrued royalty income recorded in the FY25 audited accounts.

Q: How much money is at stake and how will it affect reported results? A: The specific accrual in question amounts to £770,000. The board expects to remove that sum from the FY25 accounts, subject to auditor confirmation. Removing the accrual will reduce reported FY25 revenue and likely depress reported profit metrics. The board also said it now expects FY26 results to be significantly below market expectations.

Q: How did the market react? A: Shares fell sharply, from 19.52p on Thursday 12 February to 5.95p by mid-morning on Monday 16 February — a drop of roughly 69% over five days.

Q: Do directors say the business is still viable? A: Yes. The board said it is “confident in the underlying financial health of the business,” noting a cash balance of £2.92m as of 13 February 2026 and stating that contracts with key partners and customers remain sound. Directors framed the issue as isolated but have instigated a broader investigation.

Q: What will auditors do? A: Auditors will assess whether the newly available information constitutes a subsequent event affecting the audited FY25 financial statements. They will work with management to confirm whether accounts need correction. That process may include additional testing, third-party confirmations and, if evidence supports it, restatement of the accounts or modification of the auditor’s opinion.

Q: Could this lead to regulatory or criminal investigations? A: Yes. If the investigation uncovers deliberate misrepresentation or fraud, regulators such as the Financial Conduct Authority or criminal authorities could become involved. The company may also face civil claims from investors or contractual counterparties if losses arise from the misrepresentation.

Q: What governance steps has the board taken? A: The non-executive chairman, Martin Hunt, has taken on the role of executive chairman temporarily. The board has initiated an urgent internal investigation, informed auditors, and started a broader review of the group’s financial reporting and operations. The company is searching for an interim CEO and a permanent CEO.

Q: How should partners and customers approach their relationship with the company now? A: Partners and customers should seek written confirmation of contract status and any outstanding royalty or milestone entitlements. Where appropriate, they may request audit rights, additional reporting, or third-party verification of performance if contractual terms allow. Clear, documented communication will preserve confidence while the investigation continues.

Q: What should investors watch for next? A: Investors should monitor auditor findings, the results of any independent forensic review, any restated financial statements, the appointment of an interim and permanent CEO, further updates on FY26 guidance and public confirmations from major partners. Regulatory announcements or legal filings would also be material.

Q: What lessons does this provide for investors in small-cap biotech stocks? A: The episode underscores the importance of rigorous due diligence on governance, careful scrutiny of judgement-driven accounting items (such as accruals and milestone revenue), and the value of monitoring auditor and audit committee quality. Investors should size positions according to liquidity and governance risk and demand transparent verification of partner-based revenue streams.